Core Viewpoint - The company, Jindalai (688057.SH), is optimistic about the development prospects of stem cell technology and plans to optimize its industrial structure to seek new opportunities for future growth and enhance its risk resistance [1] Group 1 - The company intends to invest 280 million yuan in Yunnan Jici Medical Technology Co., Ltd. to acquire a 34% stake [1] - The target company's main business focuses on the research and application of autologous cell technology [1]